The pathophysiology of bladder leiomyosarcoma, a rare disease with aggressive mesenchymal tumor, is not certain, but its main symptoms are hematuria, dysuria and abdominal pain. Cases described in the literature are few. This report describes a case of a leiomyosarcoma of the urinary bladder in a 49-year-old woman. After CT scanning revealed a heterogeneously enhanced 4-cm mass involving the bladder neck and anterior wall, further examinations detected no metastatic lesion. Cystoscopy and transurethral resection of bladder tumor (TURBT) were performed. The histopathological diagnosis was leiomyosarcoma. Postoperative period was uneventful. The patient experienced complete resolution of urologic symptoms. Repeat-TURBT was performed 70 days after first surgery. The patient has remained disease-free 18 months after surgery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6038797 | PMC |
| http://dx.doi.org/10.1016/j.eucr.2018.06.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reply to Aravindh Rathinam, Jonathan Katz, Robert Marcovich, and Hemendra N. Shah's Letter to the Editor re: Michael Baboudjian, Hashim Hashim, Nikita Bhatt, et al. Summary Paper on Underactive Bladder from the European Association of Urology Guidelines on Non-neurogenic Male Lower Urinary Tract Symptoms. Eur Urol 2024;86:213-20.
Eur Urol
December 2024
Department of Urology, CHU Hôpitaux de Rouen-Hôpital Charles Nicolle, Rouen, France.
Follicular Cystitis, a Rare Diagnosis in an Emergency Setting: A case report and literature review.
Int J Surg Case Rep
December 2024
Urology A Department, University Hospital IBN SINA, Morocco.
Introduction And Importance: Follicular cystitis (FC) is a rare inflammatory disorder of the bladder that predominantly affects women. The exact cause of FC remains largely unknown, although it has been associated with inflammatory processes and bacterial infections, particularly following urinary tract infections. Regarding orphan diseases, like follicular cystitis, where large-scale trials seem virtually impossible, case reports find their place and guide the scientific community to find the best course of action.
View Article and Find Full Text PDFSafety and efficacy of low-powered holmium laser enucleation of the prostate in comparison with plasma kinetic resection of prostate.
Lasers Med Sci
December 2024
Department of Urology Surgery, Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University, No.23 Art Museum Back Street, Dongcheng District, Beijing, 100010, China.
To compare the efficacy and safety of low-power holmium laser enucleation of the prostate (LP-HoLEP) with plasma kinetic resection of prostate (PKRP). Sixty-three patients treated with transurethral LP-HoLEP (observation group) and 68 patients treated with transurethral PKRP (control group) at Beijing Hospital of Traditional Chinese Medicine from November 2019 to November 2022 were retrospectively compared with regard to operation duration, intra-operative blood loss, prostate resection ratio, postoperative bladder irrigation time, postoperative indwelling urinary catheter time, postoperative urinary incontinence incidence, International Prostate Symptom Scale (IPSS), maximum urine flow rate (Qmax), and residual urine volume (RUV). In both groups, postoperative IPSS, Qmax, and RUV were significantly improved compared to preoperative values (P < 0.
View Article and Find Full Text PDFA quality assessment of YouTube content on posterior urethral valve.
J Pediatr Urol
December 2024
Department of Urology, Gaziosmanpasa Training and Research Hospital, Istanbul, Türkiye.
Introduction: Posterior urethral valve (PUV) is a congenital condition marked by obstructing persistent urogenital membrane, leading to urinary tract infections, bladder dysfunction, and kidney damage. It affects males only, mostly suspected antenatally and confirmed in early infancy. It requires early diagnosis and intervention to prevent long-term complications.
View Article and Find Full Text PDFBiodistribution and dosimetry of the PET radioligand [F]CHDI-650 in mice for detection of mutant huntingtin aggregates.
EJNMMI Res
December 2024
μNEURO Research Centre of Excellence, Universiteitsplein 1, University of Antwerp, Antwerp, Belgium.
Background: Huntington's disease (HD) is a rare neurodegenerative disorder caused by an expansion of the CAG trinucleotide repeat in the huntingtin gene which encodes the mutant huntingtin protein (mHTT) that is associated with HD-related neuropathophysiology. Noninvasive visualization of mHTT aggregates in the brain, with positron emission tomography (PET), will allow to reliably evaluate the efficacy of therapeutic interventions in HD. This study aimed to assess the radiation burden of [F]CHDI-650, a novel fluorinated mHTT radioligand, in humans based on both in vivo and ex vivo biodistribution in mice and subsequent determination of dosimetry for dosing in humans.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!